[Diagnosis of thrombosis with a murine anti-thrombocyte antibody (99mTc-BW 4): initial clinical results].

The high incidence of deep venous thrombosis requires for successful therapy a timely and accurate diagnosis. We report early clinical results with a 99mTc-labelled anti-platelet antibody (BW 4) for the diagnosis of thrombosis or for studying platelet kinetics. 10 patients were studied of whom 7 were imaged for the detection of thrombi.

[Multiparametric analysis using radionuclide ventriculography in the assessment of left ventricular function following heart transplantation].

Left ventricular systolic and diastolic performance was evaluated by radionuclide angiography in 17 patients following cardiac transplantation and compared with normal persons. Both groups performed supine bicycle exercise during the investigation, the control group at 102 +/- 73 W and the transplanted patients at 61.2 +/- 15 W.

Tumour imaging of bladder carcinomas and their metastases with 111indium-labelled monoclonal anti-CEA antibody BW 431/26.

Fifty-one patients with muscle-infiltrating bladder carcinoma (T2-T4, N0-3, M0-1) were studied with a new imaging technique using murine monoclonal antibody directed against the carcinoembryonic antigen (CEA). A total number of 67 investigations were performed. The intact 111indium-labelled antibody (BW 431/26, Behringwerke Marburg) detected 86% of primary tumours, 93% of local and 75% of distant metastases whether there was an elevated CEA level in serum or not.

Immunoscintigraphy using a technetium-99m labelled monoclonal anti-CEA antibody in the follow-up of colorectal cancer and other tumours producing CEA.

Using the intact monoclonal IgG1 anti-CEA antibody BW 431/26 (Behringwerke Marburg, FRG) labelled with 99mTc by a new labelling procedure (Schwarz method), 72 patients suspected of tumour recurrences (colorectal cancer, n = 59) and with rising serum carcinoembryonic antigen (CEA) levels were studied. Sixty-nine of 72 studies had a positive result by immunoscintigraphy of which 52 have since been proven histologically/clinically. In six patients only immunoscintigraphy revealed a tumour recurrence while all other diagnostic modalities were negative.

[Successful immunoscintigraphic tumor detection with technetium 99m marked monoclonal anti-CEA antibodies].

Twenty patients aged 32-76 years (median 56 years) with various primary cancers or tumor recurrences (colorectal n = 14; lung, breast, medullary thyroid carcinoma n = 2, each) were studied with a technetium-99m labeled anti-CEA antibody. Intact monoclonal antibody BW 431/26 (Scintimum CEA-Tc-99m, Behringwerke AG, Marburg) was successfully labeled (Schwarz Method) by an instant 2-vial kit (labeling efficiency greater than 95% (TLC, HPLC), preserved immunoreactivity). The most frequent clinical indications were (1) the detection of tumor recurrences in patients with a steadily increasing serum CEA level (at a mean 2.